Active Filter(s):
Details:
The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline.
Lead Product(s): CPTX2309
Therapeutic Area: Immunology Product Name: CPTX2309
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 20, 2024
Details:
Capstan’s modular platform leverages the biological and technological expertise of its founding scientists and includes proprietary targeted lipid nanoparticles (tLNP) technology.
Lead Product(s): tLNP-medicated In-vivo CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Venture Fund
Deal Size: $63.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 14, 2022
Details:
The company plans to use the funds to further its mission of advancing the clinical promise of cell-based therapies by enabling precise in vivo engineering of cells with payloads necessary to benefit patients across multiple disease categories.
Lead Product(s): tLNP-medicated In-vivo CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Pfizer Ventures
Deal Size: $102.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 14, 2022